Spero therapeutics pipeline
Web1 day ago · Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel... WebJun 30, 2024 · Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Spero therapeutics pipeline
Did you know?
WebJan 14, 2024 · Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for high unmet need areas involving multi-drug-resistant bacterial … WebApr 12, 2024 · Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including...
WebOct 3, 2024 · Following the breakthrough deal with GlaxoSmithKline, Spero is in a comfortable position to advance its pipeline. The $150 million non-performance related … WebSep 22, 2024 · Spero Therapeutics ( NASDAQ:SPRO) is flying high in the pre-market session today after a multitude of positive developments. The company has entered into an exclusive license agreement with GSK for the former’s antibiotic candidate, tebipenem HBr. The late-stage product is targeted for the treatment of complicated urinary tract infections.
WebMay 3, 2024 · CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on … WebSep 22, 2024 · Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.
Web1 day ago · About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on …
WebPipeline / SPR206 SPR206 Novel Intravenous Product Candidate for Treating MDR Gram-Negative Infections in the Hospital There has been a significant decrease in the number of novel IV antibiotics in development and approved over the past 40 years for the treatment of Gram-negative infections. mouth breeding bettasWebOct 28, 2024 · Spero Therapeutics announces positive topline results from its phase 3 ADAPT-PO clinical trial of oral tebipenem HBr in complicated urinary tract infection and … mouth breeding cichlidsWebApr 14, 2024 · Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. Featured Stories mouth breathing snoring solutionmouth breathing strips shark tankWebApr 12, 2024 · Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including... mouth breeders fishWebOct 16, 2024 · CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on … mouth breeding fishWebAug 8, 2024 · Spero Therapeutics Mar 2016 - Present7 years 2 months Cambridge, MA Focused on novel treatments for Gram Negative … mouth breeders